how big is Coral Labs.?

As of Jun 06, Coral Laboratories Ltd has a market capitalization of 219.18 Cr and reported net sales of 115.01 Cr and a net profit of 24.15 Cr over the latest four quarters. Shareholder's funds are valued at 177.50 Cr, with total assets of 205.68 Cr as of Mar'24.

Market Cap: As of Jun 06, Coral Laboratories Ltd has a market capitalization of 219.18 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the company reported Net Sales of 115.01 Cr and a Net Profit of 24.15 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 177.50 Cr, and the Total Assets amount to 205.68 Cr.

When is the next results date for Coral Labs.?

No Upcoming Board Meetings

What does Coral Labs. do?

Coral Laboratories Ltd is a micro-cap pharmaceutical company established in 1997, focusing on Generic Branded, Nutraceuticals, OTC, and Herbal Medicines. As of March 2025, it reported net sales of 28 Cr and a net profit of 3 Cr, with a market cap of Rs 216 Cr.

Overview: <BR>Coral Laboratories Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of Generic Branded, Nutraceuticals, OTC, and Herbal Medicines.<BR><BR>History: <BR>Coral Laboratories Ltd was established in February 1997. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 28 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 3 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 216 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 9.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.33% <BR>Debt Equity: -0.49 <BR>Return on Equity: 13.93% <BR>Price to Book: 1.22 <BR><BR>Contact Details: <BR>Address: SF-206 Silver Oak Complex, BPC Road Vadodara Gujarat : 390020 <BR>Tel: 91-022-2500 5245/46 <BR>Email: cs@corallab.com <BR>Website: http://www.corallab.com

Who are in the management team of Coral Labs.?

As of March 2023, the management team of Coral Labs includes Sheela R Kamdar (Independent Director), Girish Dhameja (Whole-time Director), Sushma Shashi Kadkade (Director & CFO), Saurabh Shah (Independent Director), Ruchi Anjaria (Company Secretary & Compliance Officer), Malay Doshi (Independent Director), and Rajendrasinh Rana (Director). Each member contributes to the company's governance and operations.

As of March 2023, the management team of Coral Labs includes the following individuals:<BR><BR>1. Sheela R Kamdar - Independent Director<BR>2. Girish Dhameja - Whole-time Director<BR>3. Sushma Shashi Kadkade - Director & CFO<BR>4. Saurabh Shah - Independent Director<BR>5. Ruchi Anjaria - Company Secretary & Compliance Officer<BR>6. Malay Doshi - Independent Director<BR>7. Rajendrasinh Rana - Director<BR><BR>Each member plays a distinct role within the organization, contributing to its governance and operational management.

Has Coral Labs. declared dividend?

Coral Laboratories Ltd has declared a 20% dividend, amounting to 2 per share, with an ex-date of September 20, 2024. The company has shown varying total returns, with significant gains over the long term despite recent price fluctuations.

Coral Laboratories Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.33%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -24.78%, with a dividend return of 0%, resulting in a total return of -24.78%.<BR><BR>Over the past year, the price return was 18.66%, the dividend return was 0.35%, leading to a total return of 19.01%.<BR><BR>In the 2-year period, the price return was 157.18%, the dividend return was 0.84%, culminating in a total return of 158.02%.<BR><BR>For the 3-year period, the price return was 137.76%, the dividend return was 0.83%, resulting in a total return of 138.59%.<BR><BR>In the last 4 years, the price return was 31.4%, with a dividend return of 0.37%, leading to a total return of 31.77%.<BR><BR>Over the 5-year period, the price return was 214.6%, the dividend return was 1.00%, resulting in a total return of 215.6%.<BR><BR>Overall, Coral Laboratories Ltd has recently declared a dividend while showing varying total returns over different periods, with significant gains over the longer term despite some recent fluctuations in price returns.

Who are the peers of the Coral Labs.?

Coral Labs.' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, while Coral Labs. has below average growth and management risk, with a 1-year return of 22.37%.

Peers: The peers of Coral Labs. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Natural Capsules, Kimia Bioscien., Pharmaids Pharma, Alpa Laboratorie, and Syschem (India).<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have below average management risk, including Coral Labs., Natural Capsules, Kimia Bioscien., Pharmaids Pharma. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while below average growth is noted at Divi's Lab., Torrent Pharma, Kimia Bioscien., Pharmaids Pharma, and the rest. Excellent capital structure is found at Sun Pharma.Inds., Cipla, Dr Reddy's Labs., and Alpa Laboratorie, while Coral Labs., Torrent Pharma, and Natural Capsules have good capital structure, and the rest have below average capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Kimia Bioscien. has the lowest at -4.25%. Coral Labs.'s 1-year return of 22.37% is significantly higher than Kimia Bioscien. but lower than Divi's Lab. Additionally, Natural Capsules, Kimia Bioscien., Pharmaids Pharma, and Alpa Laboratorie have negative six-month returns.

What is the technical trend for Coral Labs.?

As of June 2, 2025, Coral Labs is in a bearish trend, supported by negative indicators across multiple time frames, including bearish MACD, RSI, Bollinger Bands, and moving averages.

As of 2 June 2025, the technical trend for Coral Labs has changed from mildly bearish to bearish. The weekly MACD is bearish, and the monthly MACD is mildly bearish, indicating a negative momentum shift. The RSI on a monthly basis is bearish, further supporting the bearish stance. Both the weekly and monthly Bollinger Bands are bearish, suggesting price volatility is trending downwards. Daily moving averages are also bearish, reinforcing the negative outlook. The KST is bearish on a weekly basis and mildly bearish monthly, while Dow Theory indicates a mildly bearish trend on both time frames. Overall, the current technical stance is bearish with a strong emphasis on negative indicators across multiple time frames.

Who are the top shareholders of the Coral Labs.?

The top shareholder of Coral Labs is Chetan Navinchandra Doshi, holding 51.54%. The highest public shareholder is Meeta Samir Sheth at 1.84%, with individual investors collectively owning 20.91% of the shares.

The top shareholders of Coral Labs are primarily the promoters, with Chetan Navinchandra Doshi holding the largest share at 51.54%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares. The highest public shareholder is Meeta Samir Sheth, who holds 1.84%. Additionally, individual investors collectively hold 20.91% of the shares.

Are Coral Labs. latest results good or bad?

Coral Laboratories' latest results are concerning, showing a 40.56% decline in net sales to Rs 18.82 crore and an 83.64% drop in profit before tax to Rs 1.67 crore, indicating significant challenges and an unfavorable financial outlook.

Coral Laboratories' latest results are concerning and indicate a significant decline in performance. For the quarter ending June 2025, the company reported net sales of Rs 18.82 crore, which is a sharp decrease of 40.56% compared to the same quarter last year. This marks the lowest sales figure the company has seen in the past five quarters.<BR><BR>Profit Before Tax less Other Income (PBT) also fell dramatically to Rs 1.67 crore, down 83.64% year-on-year. The operating profit reached its lowest point at Rs 2.18 crore, continuing a downward trend. Profit After Tax (PAT) was reported at Rs 2.56 crore, again the lowest in five quarters. <BR><BR>Moreover, a significant portion of the PBT, 55.11%, came from non-operating income, which raises concerns about the sustainability of the company's core business operations. Earnings per Share (EPS) dropped to Rs 7.17, reflecting declining profitability for shareholders.<BR><BR>Overall, these results suggest that Coral Laboratories is facing serious challenges, and the financial outlook appears unfavorable at this time.

How has been the historical performance of Coral Labs.?

Coral Labs has shown significant growth in net sales and profitability from March 2023 to March 2025, with net sales rising from 78.12 Cr to 115.01 Cr and profit after tax increasing from 6.45 Cr to 24.16 Cr. However, cash flow from operating activities declined from 12.00 Cr to -1.00 Cr during the same period.

Answer:<BR>The historical performance of Coral Labs shows a significant upward trend in net sales and profitability over the past few years.<BR><BR>Breakdown:<BR>Coral Labs has demonstrated a strong growth trajectory in net sales, increasing from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. This growth is reflected in the total operating income, which also rose from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. The company's operating profit (PBDIT) excluding other income surged from 3.81 Cr in March 2023 to 26.24 Cr in March 2025, indicating improved operational efficiency. Profit before tax followed a similar trend, climbing from 8.23 Cr in March 2023 to 32.47 Cr in March 2025, while profit after tax increased from 6.45 Cr to 24.16 Cr in the same period. The earnings per share (EPS) also saw a substantial rise from 18.07 in March 2023 to 67.68 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from 174.35 Cr in March 2023 to 229.46 Cr in March 2025, with total liabilities increasing from 174.35 Cr to 229.46 Cr, indicating a proportional growth in the company's financial structure. Cash flow from operating activities, however, showed a negative trend, moving from a positive 12.00 Cr in March 2023 to a negative 1.00 Cr in March 2025, suggesting challenges in cash generation despite strong profit growth. Overall, Coral Labs has improved its financial performance significantly over the years, particularly in sales and profitability metrics.

Should I buy, sell or hold Coral Labs.?

Is Coral Labs. overvalued or undervalued?

As of November 17, 2025, Coral Labs is considered undervalued with a PE ratio of 10.25 and an EV to EBIT of 5.62, significantly lower than its expensive industry peers, suggesting potential for recovery despite a challenging year with a -40.17% stock return.

As of 17 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 10.25, an EV to EBIT of 5.62, and a Price to Book Value of 0.85, which all suggest a favorable valuation relative to its peers.<BR><BR>In comparison to its industry peers, Coral Labs stands out with a significantly lower PE ratio than Sun Pharma (36.69) and Divi's Lab (69.78), both classified as expensive. Additionally, Coral Labs' EV to EBITDA of 4.95 is also more attractive than the industry average, reinforcing its undervalued status. Despite a challenging year with a stock return of -40.17%, the company's valuation metrics indicate potential for recovery and growth compared to the Sensex.

Which are the latest news on Coral Labs.?

Why is Coral Labs. falling/rising?

As of 04-Dec, Coral Laboratories Ltd's stock price is declining at 469.75, down -2.8 (-0.59%), with a total drop of -4.51% over the last three days. The stock has significantly underperformed against the Sensex across various time frames, trading below its moving averages, indicating a bearish trend.

As of 04-Dec, Coral Laboratories Ltd is experiencing a decline in its stock price, currently at 469.75, which reflects a change of -2.8 (-0.59%). The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of -4.51% during this period. Although the stock opened today with a gain of 3.27% and reached an intraday high of Rs 488, it subsequently dropped to a low of Rs 462, indicating volatility within the trading session.<BR><BR>In terms of performance relative to the benchmark, Coral Labs has shown significant underperformance over various time frames. Over the past week, the stock has decreased by -3.23%, while the Sensex has only fallen by -0.53%. In the last month, Coral Labs has declined by -5.01%, contrasting sharply with the Sensex's increase of +2.16%. Year-to-date, the stock is down -38.42%, while the Sensex has gained +9.12%. Over the past year, Coral Labs has seen a decline of -42.67%, compared to a modest +5.32% increase in the Sensex.<BR><BR>Additionally, the stock is trading below its moving averages across multiple time frames (5-day, 20-day, 50-day, 100-day, and 200-day), which typically signals a bearish trend. Despite a notable increase in delivery volume by 197.95% against the 5-day average, the overall sentiment remains negative, contributing to the stock's downward trajectory. Thus, the combination of recent price declines, poor relative performance against the benchmark, and trading below moving averages are key factors contributing to the current fall in Coral Laboratories Ltd's stock price.